Guanfacine is not a stimulant. It belongs to a completely different drug class called centrally acting alpha-2A adrenergic receptor agonists, and it works through a distinct mechanism in the brain. Because guanfacine is commonly prescribed for ADHD, a condition most people associate with stimulant medications like Adderall or Ritalin, the confusion is understandable. But guanfacine differs from stimulants in how it affects the brain, what side effects it causes, and whether it carries any risk of abuse.
How Guanfacine Works in the Brain
Stimulant medications treat ADHD by increasing levels of norepinephrine and dopamine, two chemical messengers that sharpen focus and attention. They do this primarily by blocking the transporters that recycle these chemicals, leaving more of them available at nerve connections.
Guanfacine takes a different route entirely. It activates specific receptors (alpha-2A receptors) on brain cells in the prefrontal cortex, the region responsible for planning, impulse control, and working memory. When these receptors are activated, they strengthen the electrical connections between neurons in that area, essentially helping the prefrontal cortex function more efficiently. Research from Yale School of Medicine has shown that guanfacine does this by preventing certain ion channels from opening on nerve cell branches, which keeps the signal strong instead of letting it dissipate.
Interestingly, stimulants and guanfacine end up acting on some of the same receptors in the prefrontal cortex, just through different paths. Stimulants boost the brain’s own norepinephrine, which then activates those same alpha-2A receptors indirectly. Guanfacine activates them directly. This overlap helps explain why both drug types can improve ADHD symptoms despite being pharmacologically very different.
What Guanfacine Is Approved to Treat
Guanfacine comes in two forms with different approved uses. The immediate-release version (Tenex) is approved for managing high blood pressure in adults. The extended-release version (Intuniv) is approved for treating ADHD in children and adolescents ages 6 to 17, both as a standalone treatment and as an add-on to stimulant medications. Guanfacine was originally developed as a blood pressure drug, and its effects on attention and behavior were recognized later.
Guanfacine vs. Stimulants for ADHD
One key question for anyone considering guanfacine is how well it works compared to stimulants. A controlled comparative study published in the Journal of the American Academy of Child and Adolescent Psychiatry found that guanfacine alone produced ADHD symptom improvements that were statistically comparable to those seen with a stimulant (d-methylphenidate). The effect size difference between the two was essentially zero on total ADHD symptom scores, inattention scores, and hyperactivity-impulsivity scores. Combining the two medications didn’t produce meaningfully greater benefits than either one alone in that study.
That said, stimulants remain the first-line treatment for ADHD in most clinical guidelines because the broader body of evidence, across many more trials, generally shows larger average effect sizes for stimulants. Guanfacine is typically considered when stimulants aren’t tolerated, cause problematic side effects, or don’t fully control symptoms on their own.
Adding Guanfacine to a Stimulant
For children and teens who still have significant ADHD symptoms on a stimulant alone, adding guanfacine can help. A randomized, double-blind trial found that adding extended-release guanfacine to a stimulant produced significantly greater symptom reduction than adding a placebo. Importantly, drug interaction studies have confirmed that taking guanfacine alongside long-acting methylphenidate or lisdexamfetamine doesn’t meaningfully change how the body processes either medication. The safety profile of the combination has been consistent with what’s expected from each drug individually.
Side Effects Are Different From Stimulants
The side effect profile of guanfacine is almost the opposite of what stimulants typically cause. Stimulants tend to suppress appetite, cause insomnia, raise heart rate, and increase blood pressure. Guanfacine does none of those things. Instead, its most common side effects reflect its blood-pressure-lowering origins: drowsiness, dizziness (especially when standing up quickly), and fatigue. Because of the drowsiness, taking the dose at bedtime is a common strategy to minimize daytime sleepiness.
Guanfacine can lower blood pressure and heart rate, so these are monitored during treatment. Dizziness or lightheadedness when going from sitting to standing is one of the more noticeable effects, particularly early on. Standing up slowly helps. One important caution: stopping guanfacine suddenly can cause a rebound spike in blood pressure and heart rate, so the dose needs to be tapered gradually rather than discontinued all at once.
No Abuse Potential
Unlike stimulant ADHD medications, which are classified as Schedule II controlled substances due to their potential for misuse, guanfacine is not a controlled substance at all. It has no known potential for abuse or dependence. This distinction matters for several reasons. Prescriptions are simpler to manage since they don’t require the special prescribing restrictions that controlled substances do. For families concerned about substance misuse risk, particularly in teenagers, guanfacine removes that variable from the equation. And unlike stimulants, guanfacine doesn’t produce euphoria or the “high” that drives misuse, because it doesn’t flood the brain with dopamine.